40069-10-1

Basic information

• Product Name: ethyl 4-(N'-hydroxycarbamimidoyl)benzoate
• CAS NO: 40069-10-1
• Molecular Weight: 208.217
• Mol File: 40069-10-1.mol

Chemical Properties

• CAS DataBase Reference: ethyl 4-(N'-hydroxycarbamimidoyl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-(N'-hydroxycarbamimidoyl)benzoate(40069-10-1)
• EPA Substance Registry System: ethyl 4-(N'-hydroxycarbamimidoyl)benzoate(40069-10-1)

Safety Data

• Hazardous Substances Data: 40069-10-1(Hazardous Substances Data)

Upstream product

• 7153-22-2 ethyl 4-cyanobenzoate 

Downstream Products

• 1402448-90-1 (Z)-dimethyl-4-{(ethoxycarbonyl)benzimidamidoxy}but-2-enedioate 
• 1402448-88-7 (E)-dimethyl-4-{(ethoxycarbonyl)benzimidamidoxy}but-2-enedioate 
• 1360573-20-1 C₃₁H₂₆N₂O₃ 
• 1360573-21-2 C₂₉H₂₂N₂O₃ 
• 1444001-62-0 ethyl 4-(N'-((ethoxycarbonyl)oxy)carbamimidoyl)benzoate 
• 1444001-08-4 (S)-ethyl 1-(4-(2-oxo-5-((4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)benzamido)methyl)oxazolidin-3-yl)phenyl)piperidine-4-carboxylate 
• 189365-92-2 4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)benzoic acid 
• 1444001-63-1 ethyl 4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)benzoate 
• 23610-05-1 4-(N-hydroxycarbamimidoyl)-benzoic acid 

Relevant articles and documents

LKB1-AMPK ACTIVATORS FOR THERAPEUTIC USE IN POLYCYSTIC KIDNEY DISEASE

Compounds are provided for use in treating polycystic kidney disease (PKD) and in associated methods that include a method of modulating (e.g., activating) Liver kinase Bl (LKBI); and a method of modulating (e.g., decreasing activity) mammalian target of

Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores

Dual antithrombotic agents acting as anticoagulants and aggregation inhibitors could have substantial advantages over currently prescribed combinations of antithrombotic drugs. Herein, we report compounds with moderate inhibitory activity for factor Xa an

Design and synthesis of boron containing potential pan-RAR inverse agonists

We designed and successfully synthesized the compounds 5 and 8 as potential pan-RAR (retinoic acid receptor) agonists. These two compounds were designed based on an existing pan-RAR agonist (BMS493). We synthesized compound 5, in which the carboxylic acid

Rapid catalyst identification for the synthesis of the pyrimidinone core of HIV integrase inhibitors

A microscale chemistry improvement engine: A pre-dosed microscale high-throughput experimentation additives platform enables rapid, serendipitous reaction improvement. This platform allowed one chemist to set up 475 experiments and analyze the results using MISER chromatography in a single day, thus resulting in two high-quality catalytic systems for the construction of the title compound 1. Support for a single-electron transfer mechanism was obtained. Copyright

AMINO-PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS

The invention relates to novel amino-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

THIOPHENE DERIVATIVES AS AGONISTS OF S1P1/EDG1

The invention relates to novel thiophene derivatives (1), their preparation and their use as pharmaceutically active compounds.Said compounds particularly act as immunomodulating agents. Formula (I).

AMINO- PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS

The invention relates to novel amino-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.